First Participant Dosed in ACT-EARLY: A Primary Prevention Study for Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma announced the first participant has been dosed in ACT-EARLY, the first-ever primary prevention study for transthyretin amyloid cardio...
Home/KnloSights/Clinical Trial Updates/First Participant Dosed in ACT-EARLY: A Primary Prevention Study for Transthyretin Amyloid Cardiomyopathy